Skip to Main Content

Amneal Pharmaceuticals, Inc. Class A Common Stock

AMRX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
AMRX Income Statement
AMRX Balance Sheet
AMRX Cash Flow
AMRX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
AMRX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AMRX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by AMRX's directors and management

Government lobbying spending instances

  • $170,000 Nov 12, 2024 Issue: Health Issues
  • $170,000 Nov 12, 2024 Issue: Health Issues
  • $730,000 Apr 22, 2024 Issue: Health Issues
  • $40,000 Apr 20, 2022 Issue: Pharmacy
  • $60,000 Jan 20, 2022 Issue: Pharmacy
  • $60,000 Oct 20, 2021 Issue: Pharmacy
  • $60,000 Jul 20, 2021 Issue: Pharmacy
  • $60,000 Apr 20, 2021 Issue: Pharmacy
  • $60,000 Jan 21, 2021 Issue: Pharmacy
  • $60,000 Oct 20, 2020 Issue: Pharmacy
  • $50,000 Jul 20, 2020 Issue: Pharmacy
  • $20,000 Feb 01, 2019 Issue: None
  • $20,000 Jan 18, 2019 Issue: None
  • $20,000 Oct 08, 2018 Issue: None
  • $20,000 Jul 12, 2018 Issue: None
  • $40,000 Apr 16, 2018 Issue: Health Issues Budget/Appropriations
  • $40,000 Jan 20, 2018 Issue: Trade (domestic/foreign) Health Issues
  • $40,000 Dec 28, 2017 Issue: Health Issues
  • $40,000 Oct 19, 2017 Issue: Health Issues
  • $40,000 Jul 19, 2017 Issue: Health Issues
  • $40,000 Apr 20, 2017 Issue: Health Issues
  • $40,000 Oct 20, 2016 Issue: Pharmacy Health Issues
  • $40,000 Jul 19, 2016 Issue: Health Issues Pharmacy
  • $40,000 Apr 14, 2016 Issue: Pharmacy Health Issues
  • $40,000 Jan 15, 2016 Issue: Pharmacy Budget/Appropriations Copyright/Patent/Trademark Health Issues
  • $40,000 Oct 19, 2015 Issue: Pharmacy Health Issues Copyright/Patent/Trademark
  • $40,000 Jul 14, 2015 Issue: Pharmacy Health Issues Budget/Appropriations
  • $10,000 Apr 17, 2015 Issue: Health Issues Medicare/Medicaid Budget/Appropriations Pharmacy
  • $40,000 Apr 17, 2015 Issue: Health Issues Budget/Appropriations Pharmacy
  • $30,000 Jan 20, 2015 Issue: Pharmacy
  • $20,000 Jan 18, 2015 Issue: Insurance Health Issues Taxation/Internal Revenue Code Medicare/Medicaid Budget/Appropriations Pharmacy
  • $10,000 Oct 18, 2014 Issue: Pharmacy Taxation/Internal Revenue Code Health Issues Budget/Appropriations Insurance Food Industry (safety, labeling, etc.) Medicare/Medicaid
  • $30,000 Oct 15, 2014 Issue: Pharmacy
  • $30,000 Jul 18, 2014 Issue: Pharmacy Health Issues Budget/Appropriations
  • $30,000 Apr 16, 2014 Issue: Pharmacy Health Issues Budget/Appropriations
  • $25,000 Jan 16, 2014 Issue: Budget/Appropriations Health Issues Pharmacy

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of AMRX in WallStreetBets Daily Discussion

AMRX News

Recent insights relating to AMRX

CNBC Recommendations

Recent picks made for AMRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AMRX

AMRX Top Shareholders
Shareholder
Shares Held
AMRX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

AMRX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AMRX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top